Biolinq
Biosensing platform for metabolic health
- 101-200 employees
- Healthcare
- B2B
- Deep Tech
- MedTech
- Sorrento Valley, San Diego, CA
Jump to section
Company mission
To reach more people that are in need of simple solutions to improve metabolic health.
Our take
Metabolic health is the ability of the body to respond to food in a beneficial way. Bad metabolic health can lead to conditions such as diabetes. Biolinq’s wearable MedTech enters a similar market as smart watches and Fitbits, but focuses specifically on glucose levels.
Biolinq's patch is placed on the upper forearm and utilizes miniscule electrochemical sensors. A display indicates when glucose levels are at an optimum level, and works in real time for optimized and reliable insights. The device stands out against competing device by being "so small that you can barely feel it".
The company's oversubscribed 2024 funding round exemplifies how attractive the offering is to investors, as well as to consumers wanting to control their blood sugar level. On top of this, the company secured FDA clearance in 2025 for its needle-free continuous glucose monitor. Putting it in a very good position going forward.
Steph
Company Specialist at Welcome to the Jungle
Funding (last 2 of 6 rounds)
Apr 2025
$100m
SERIES C
Apr 2024
$58m
LATE VC
Total funding: $312.9m
Leadership
Jared Tangney
(Co-Founder, President & CTO)Previously co-founded Electrozyme where they served as the COO and CEO.